Company Overview - Delcath Systems, Inc. (NASDAQ:DCTH) was founded on August 5, 1988, and is headquartered in Queensbury, New York. The company specializes in developing interventional oncology therapies for primary and metastatic liver cancers, including the Hepzato and Chemosat Hepatic Delivery System [4]. Financial Performance - Delcath Systems reported preliminary, unaudited fourth-quarter revenue of approximately $20.7 million and full-year 2025 revenue of $85.2 million, driven primarily by Hepzato sales totaling about $19.0 million for the quarter and $78.8 million for the year [3]. - The company demonstrated strong operating cash flow and minimal leverage, which supports internal funding of clinical programs and a previously announced share repurchase plan [3]. Analyst Ratings - Clear Street raised its price target on Delcath Systems to $29 from $28 while maintaining a Buy rating, citing that Hepzato has become a steadier revenue contributor with improved predictability and sufficient cash generation to support expansion into additional indications [1][3].

Company Overview - Delcath Systems, Inc. (NASDAQ:DCTH) specializes in interventional oncology treatments for liver cancers, with main products including the HEPZATO KIT and CHEMOSAT Hepatic Delivery System [4] Financial Performance - For fiscal Q3 2025, Delcath reported revenue of $20.6 million, a significant increase from $11.2 million in the same quarter last year [2] - The company's EPS was $0.02, exceeding consensus estimates by $0.08 [2] - Revenue from the HEPZATO KIT grew to $19.3 million from $10 million year-over-year, while CHEMOSAT revenue increased from $1.2 million to $1.3 million [2] - Gross margins improved from 85% to 87% during the same period [2] Guidance and Outlook - Despite strong Q3 performance, management lowered full-year revenue guidance to a range of $83 million to $85 million, down from the previous range of $93 million to $96 million [3] - The reduction in guidance is attributed to a slowdown in new patient starts, partially due to seasonal factors [3] Analyst Rating - Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Delcath but lowered the price target from $31 to $30 [1]